Next Article in Journal
Autophagy Declines with Premature Skin Aging resulting in Dynamic Alterations in Skin Pigmentation and Epidermal Differentiation
Next Article in Special Issue
Multiple Recombination Events and Strong Purifying Selection at the Origin of SARS-CoV-2 Spike Glycoprotein Increased Correlated Dynamic Movements
Previous Article in Journal
Patterns of Expansion and Expression Divergence of the Polygalacturonase Gene Family in Brassica oleracea
Previous Article in Special Issue
Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations
Review

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells

1
Department of Pharmacy, University of Napoli “Federico II”, via D. Montesano 49, 80131 Napoli, Italy
2
Dompé Farmaceutici SpA, via Campo di Pile, 67100 L’Aquila, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(16), 5707; https://doi.org/10.3390/ijms21165707
Received: 15 June 2020 / Revised: 7 August 2020 / Accepted: 7 August 2020 / Published: 9 August 2020
The pandemic evolution of SARS-CoV-2 infection is forcing the scientific community to unprecedented efforts to explore all possible approaches against COVID-19. In this context, targeting virus entry is a promising antiviral strategy for controlling viral infections. The main strategies pursued to inhibit the viral entry are considering both the virus and the host factors involved in the process. Primarily, direct-acting antivirals rely on inhibition of the interaction between ACE2 and the receptor binding domain (RBD) of the Spike (S) protein or targeting the more conserved heptad repeats (HRs), involved in the membrane fusion process. The inhibition of host TMPRSS2 and cathepsins B/L may represent a complementary strategy to be investigated. In this review, we discuss the development entry inhibitors targeting the S protein, as well as the most promising host targeting strategies involving TMPRSS2 and CatB/L, which have been exploited so far against CoVs and other related viruses. View Full-Text
Keywords: SARS-CoV-2 entry inhibitors; COVID-19; coronavirus; spike; TMPRSS2; cathepsins; small molecules inhibitors; peptides inhibitors SARS-CoV-2 entry inhibitors; COVID-19; coronavirus; spike; TMPRSS2; cathepsins; small molecules inhibitors; peptides inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Cannalire, R.; Stefanelli, I.; Cerchia, C.; Beccari, A.R.; Pelliccia, S.; Summa, V. SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. Int. J. Mol. Sci. 2020, 21, 5707. https://doi.org/10.3390/ijms21165707

AMA Style

Cannalire R, Stefanelli I, Cerchia C, Beccari AR, Pelliccia S, Summa V. SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. International Journal of Molecular Sciences. 2020; 21(16):5707. https://doi.org/10.3390/ijms21165707

Chicago/Turabian Style

Cannalire, Rolando, Irina Stefanelli, Carmen Cerchia, Andrea R. Beccari, Sveva Pelliccia, and Vincenzo Summa. 2020. "SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells" International Journal of Molecular Sciences 21, no. 16: 5707. https://doi.org/10.3390/ijms21165707

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop